328 related articles for article (PubMed ID: 12672070)
21. Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of Cryptococcus neoformans.
McFadden DC; Casadevall A
J Immunol; 2004 Mar; 172(6):3670-7. PubMed ID: 15004170
[TBL] [Abstract][Full Text] [Related]
22. Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans.
Retini C; Casadevall A; Pietrella D; Monari C; Palazzetti B; Vecchiarelli A
J Immunol; 1999 Feb; 162(3):1618-23. PubMed ID: 9973421
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of HIV entry by extracellular glucuronoxylomannan of Cryptococcus neoformans.
Yi HA; Panepinto JC; Jacobs A
Microb Pathog; 2012 Jan; 52(1):25-30. PubMed ID: 21983597
[TBL] [Abstract][Full Text] [Related]
24. Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection.
Abadi J; Pirofski La
J Infect Dis; 1999 Sep; 180(3):915-9. PubMed ID: 10438394
[TBL] [Abstract][Full Text] [Related]
25. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
[TBL] [Abstract][Full Text] [Related]
26. Cryptococcal glucuronoxylomannan interferes with neutrophil rolling on the endothelium.
Ellerbroek PM; Ulfman LH; Hoepelman AI; Coenjaerts FE
Cell Microbiol; 2004 Jun; 6(6):581-92. PubMed ID: 15104598
[TBL] [Abstract][Full Text] [Related]
27. Scanning electron microscopy of encapsulated and non-encapsulated Cryptococcus neoformans and the effect of glucose on capsular polysaccharide release.
Cleare W; Casadevall A
Med Mycol; 1999 Aug; 37(4):235-43. PubMed ID: 10421858
[TBL] [Abstract][Full Text] [Related]
28. Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: implications for vaccine development.
May RJ; Beenhouwer DO; Scharff MD
J Immunol; 2003 Nov; 171(9):4905-12. PubMed ID: 14568972
[TBL] [Abstract][Full Text] [Related]
29. C1q enhances the phagocytosis of Cryptococcus neoformans blastospores by human monocytes.
Bobak DA; Washburn RG; Frank MM
J Immunol; 1988 Jul; 141(2):592-7. PubMed ID: 3290342
[TBL] [Abstract][Full Text] [Related]
30. The heat shock protein (Hsp) 70 of Cryptococcus neoformans is associated with the fungal cell surface and influences the interaction between yeast and host cells.
Silveira CP; Piffer AC; Kmetzsch L; Fonseca FL; Soares DA; Staats CC; Rodrigues ML; Schrank A; Vainstein MH
Fungal Genet Biol; 2013 Nov; 60():53-63. PubMed ID: 23954835
[TBL] [Abstract][Full Text] [Related]
31. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
Fleuridor R; Lees A; Pirofski L
J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
[TBL] [Abstract][Full Text] [Related]
32. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
33. Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo.
Yauch LE; Mansour MK; Levitz SM
Infect Immun; 2005 Dec; 73(12):8429-32. PubMed ID: 16299344
[TBL] [Abstract][Full Text] [Related]
34. Regulated Release of Cryptococcal Polysaccharide Drives Virulence and Suppresses Immune Cell Infiltration into the Central Nervous System.
Denham ST; Verma S; Reynolds RC; Worne CL; Daugherty JM; Lane TE; Brown JCS
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29203547
[No Abstract] [Full Text] [Related]
35. Glucuronoxylomannan-mediated interaction of Cryptococcus neoformans with human alveolar cells results in fungal internalization and host cell damage.
Barbosa FM; Fonseca FL; Holandino C; Alviano CS; Nimrichter L; Rodrigues ML
Microbes Infect; 2006 Feb; 8(2):493-502. PubMed ID: 16293436
[TBL] [Abstract][Full Text] [Related]
36. Phagosome extrusion and host-cell survival after Cryptococcus neoformans phagocytosis by macrophages.
Alvarez M; Casadevall A
Curr Biol; 2006 Nov; 16(21):2161-5. PubMed ID: 17084702
[TBL] [Abstract][Full Text] [Related]
37. Mobility of human neutrophils in response to Cryptococcus neoformans cells, culture filtrate antigen, and individual components of the antigen.
Dong ZM; Murphy JW
Infect Immun; 1993 Dec; 61(12):5067-77. PubMed ID: 8225584
[TBL] [Abstract][Full Text] [Related]
38. Immunoregulation by capsular components of Cryptococcus neoformans.
Vecchiarelli A
Med Mycol; 2000 Dec; 38(6):407-17. PubMed ID: 11204878
[TBL] [Abstract][Full Text] [Related]
39. Receptor-mediated recognition of Cryptococcus neoformans.
Levitz SM
Nihon Ishinkin Gakkai Zasshi; 2002; 43(3):133-6. PubMed ID: 12145626
[TBL] [Abstract][Full Text] [Related]
40. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.
Deshaw M; Pirofski LA
Clin Exp Immunol; 1995 Mar; 99(3):425-32. PubMed ID: 7882565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
